Maria Giovanna Marrosu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8298505/publications.pdf

Version: 2024-02-01

227 papers	7,693 citations	50170 46 h-index	82410 72 g-index
231 all docs	231 docs citations	231 times ranked	9384 citing authors

#	Article	IF	Citations
1	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
2	PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity. Multiple Sclerosis Journal, 2021, 27, 1332-1340.	1.4	13
3	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsingâ€“Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). Frontiers in Neurology, 2021, 12, 637615.	1.1	1
4	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. Disability and Rehabilitation, 2020, 42, 737-742.	0.9	6
5	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	1.7	20
6	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101886.	0.9	3
7	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsingâ€“Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	1.0	22
8	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. Neurotherapeutics, 2019, 16, 797-807.	2.1	17
9	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	2.8	118
10	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	0.9	59
11	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. Multiple Sclerosis Journal, 2019, 25, 23-30.	1.4	11
12	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A caseâ€“control MRI study. Journal of Neurology, 2018, 265, 1096-1101.	1.8	14
13	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. Multiple Sclerosis and Related Disorders, 2018, 20, 104-108.	0.9	9
14	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. Multiple Sclerosis and Related Disorders, 2018, 22, 8-11.	0.9	9
15	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. Journal of Neurology, 2018, 265, 424-430.	1.8	21
16	Long-term follow-up more than 10Âyears after HSCT: a monocentric experience. Journal of Neurology, 2018, 265, 410-416.	1.8	10
17	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work, 2018, 60, 263-270.	0.6	30
18	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. Journal of Neurology, 2018, 265, 1328-1333.	1.8	15

#	Article	IF	Citations
19	Quantitative assessment of the effects of 6 months of adapted physical activity on gait in people with multiple sclerosis: a randomized controlled trial. Disability and Rehabilitation, 2018, 40, 144-151.	0.9	21
20	The burden of multiple sclerosis and patientsâ€™ coping strategies. BMJ Supportive and Palliative Care, 2018, 8, 38-40.	0.8	25
21	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. Multiple Sclerosis Journal, 2018, 24, 231-233.	1.4	3
22	PML in a person with multiple sclerosis. Neurology, 2018, 90, 83-85.	1.5	23
23	A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1765-1788.	0.9	7
24	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. Multiple Sclerosis and Related Disorders, 2018, 23, 83-87.	0.9	9
25	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurology, 2018, 18, 67.	0.8	27
26	Association between brain atrophy and cognitive motor interference in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 208-211.	0.9	10
27	Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs. Neurological Sciences, 2017, 38, 589-594.	0.9	10
28	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, 2017, 15, 1-6.	0.9	26
29	Charcotâ€“Marieâ€“Tooth disease: genetic subtypes in the Sardinian population. Neurological Sciences, 2017, 38, 1019-1025.	0.9	11
30	Smoothness of gait detects early alterations of walking in persons with multiple sclerosis without disability. Gait and Posture, 2017, 58, 307-309.	0.6	39
31	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. International Journal of Biochemistry and Cell Biology, 2017, 93, 148-155.	1.2	44
32	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	0.9	30
33	Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 173-180.	1.4	13
34	Soluble BAFF Level Is Not Correlated to Mycobacterium avium Subspecies Paratuberculosis Antibodies and Increases After Interferon-Î² Therapy in Multiple Sclerosis Patients. Journal of Molecular Neuroscience, 2016, 60, 91-93.	1.1	8
35	¹ H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e185.	3.1	68
36	Epstein Barr Virus and Mycobacterium avium subsp. paratuberculosis peptides are recognized in sera and cerebrospinal fluid of MS patients. Scientific Reports, 2016, 6, 22401.	1.6	42

#	Article	IF	Citations
37	The Required Coefficient of Friction for evaluating gait alterations in people with Multiple Sclerosis during gait. Multiple Sclerosis and Related Disorders, 2016, 10, 174-178.	0.9	6
38	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	1.5	40
39	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. Multiple Sclerosis and Related Disorders, 2016, 10, 187-191.	0.9	61
40	Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. Scientific Reports, 2016, 6, 29268.	1.6	18
41	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
42	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. Multiple Sclerosis and Related Disorders, 2016, 7, 65-67.	0.9	5
43	Progressive apraxia of speech in a patient with a C9orf72 mutation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 608-609.	1.1	1
44	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
45	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Neurological Sciences, 2016, 37, 437-442.	0.9	7
46	Phenotypic variability related to C9orf72 mutation in a large Sardinian kindred. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 245-248.	1.1	6
47	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurological Sciences, 2016, 37, 613-622.	0.9	14
48	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. PLoS ONE, 2016, 11, e0163313.	1.1	15
49	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	0.8	31
50	Multiple Spontaneous Cerebral Microbleeds and Leukoencephalopathy in PSEN1-Associated Familial Alzheimerâ€™s Disease: Mirror of Cerebral Amyloid Angiopathy?. Journal of Alzheimer's Disease, 2015, 47, 535-538.	1.2	6
51	Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2015, 11, 759.	0.9	10
52	Effectiveness and Limitations of Unsupervised Home-Based Balance Rehabilitation with Nintendo Wii in People with Multiple Sclerosis. BioMed Research International, 2015, 2015, 1-8.	0.9	22
53	Dynamical insights into the differential characteristics of Mycobacterium avium subsp. paratuberculosis peptide binding to HLA-DRB1 proteins associated with multiple sclerosis. New Journal of Chemistry, 2015, 39, 1355-1366.	1.4	23
54	Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. Journal of the Neurological Sciences, 2015, 349, 249-250.	0.3	12

#	Article	IF	Citations
55	Attitude towards physical activity in patients with multiple sclerosis: a cohort study. Neurological Sciences, 2015, 36, 889-893.	0.9	19
56	Constructional apraxia in frontotemporal dementia associated with the C9orf72 mutation: Broadening the clinical and neuropsychological phenotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 8-15.	1.1	10
57	Walking improvements with nabiximols in patients with multiple sclerosis. Journal of Neurology, 2015, 262, 2472-2477.	1.8	40
58	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopaâ€“carbidopa intestinal gel infusion. Parkinsonism and Related Disorders, 2015, 21, 968-971.	1.1	23
59	Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients. Journal of Neuroimmunology, 2015, 280, 66-68.	1.1	29
60	Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. Journal of Neurology, 2015, 262, 375-384.	1.8	50
61	Progressive multiple sclerosis and mood disorders. Neurological Sciences, 2015, 36, 1625-1631.	0.9	14
62	Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis. Journal of the Neurological Sciences, 2015, 358, 339-344.	0.3	57
63	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	1.5	19
64	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	3.7	76
65	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. Neurological Sciences, 2015, 36, 2213-2220.	0.9	1
66	Relationship between gait initiation and disability in individuals affected by multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 594-597.	0.9	8
67	C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinsonâ€™s disease complicated by psychosis or dementia in a Sardinian population. Journal of Neurology, 2015, 262, 2498-2503.	1.8	25
68	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. Journal of the Neurological Sciences, 2015, 357, 229-234.	0.3	6
69	Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel. Parkinsonism and Related Disorders, 2015, 21, 1383-1384.	1.1	1
70	The burden of multiple sclerosis variants in continental Italians and Sardinians. Multiple Sclerosis Journal, 2015, 21, 1385-1395.	1.4	10
71	Influence of treatments in multiple sclerosis disability: A cohort study. Multiple Sclerosis Journal, 2015, 21, 433-441.	1.4	32
72	Human interferon regulatory factor 5 homologous epitopes ofEpstein-Barrvirus andMycobacterium aviumsubsp.paratuberculosisinduce a specific humoral and cellular immune response in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 984-995.	1.4	37

#	Article	IF	Citations
73	The current role of mitoxantrone in the treatment of multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 607-616.	1.4	36
74	Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35â€“55, in multiple sclerosis patients. Journal of the Neurological Sciences, 2014, 347, 78-81.	0.3	10
75	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	0.9	66
76	Neuroactive steroid levels in plasma and cerebrospinal fluid of male multiple sclerosis patients. Journal of Neurochemistry, 2014, 130, 591-597.	2.1	48
77	A Novel LIPE Nonsense Mutation Found Using Exome Sequencing in Siblings With Late-Onset Familial PartialÂLipodystrophy. Canadian Journal of Cardiology, 2014, 30, 1649-1654.	0.8	58
78	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. Muscle and Nerve, 2014, 49, 928-930.	1.0	13
79	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	0.8	99
80	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurological Sciences, 2014, 35, 401-408.	0.9	19
81	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	0.9	30
82	Genetic architecture of ALS in Sardinia. Neurobiology of Aging, 2014, 35, 2882.e7-2882.e12.	1.5	60
83	Antigenic peptide molecular recognition by the DRB1â€“DQB1 haplotype modulates multiple sclerosis susceptibility. Molecular BioSystems, 2014, 10, 2043-2054.	2.9	24
84	Novel characterization of gait impairments in people with multiple sclerosis by means of the gait profile score. Journal of the Neurological Sciences, 2014, 345, 159-163.	0.3	52
85	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	0.8	27
86	The risk of Bipolar Disorders in Multiple Sclerosis. Journal of Affective Disorders, 2014, 155, 255-260.	2.0	61
87	Epsteinâ€“Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 2014, 270, 51-55.	1.1	56
88	Antigenic epitopes of MAP2694 homologous to T-cell receptor gamma-chain are highly recognized in multiple sclerosis Sardinian patients. Molecular Immunology, 2014, 57, 138-140.	1.0	26
89	C9<scp>ORF</scp>72 repeat expansion and bipolar disorder â€“ is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. Bipolar Disorders, 2014, 16, 667-668.	1.1	11
90	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. Journal of Affective Disorders, 2014, 167, 192-197.	2.0	40

#	Article	IF	Citations
91	Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis. Inflammation and Allergy: Drug Targets, 2014, 13, 134-143.	1.8	4
92	Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?. Journal of Neurology, 2013, 260, 1155-1157.	1.8	38
93	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	0.9	46
94	The p.A382T TARDBP gene mutation in Sardinian patients affected by Parkinson's disease and other degenerative parkinsonisms. Neurogenetics, 2013, 14, 161-166.	0.7	38
95	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. BMC Neurology, 2013, 13, 177.	0.8	48
96	Anti Mycobacterium avium subsp. paratuberculosis heat shock protein 70 antibodies in the sera of Sardinian patients with multiple sclerosis. Journal of the Neurological Sciences, 2013, 335, 131-133.	0.3	24
97	Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica, 2013, 127, 301-308.	1.0	10
98	EBNA-1 IgG titers in Sardinian multiple sclerosis patients and controls. Journal of Neuroimmunology, 2013, 264, 120-122.	1.1	25
99	Mycobacterium avium subsp. paratuberculosis and multiple sclerosis in Sardinian patients: epidemiology and clinical features. Multiple Sclerosis Journal, 2013, 19, 1437-1442.	1.4	31
100	Muscle <scp>MRI</scp> in female carriers of emerinopathy. European Journal of Neurology, 2013, 20, e127.	1.7	1
101	Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations. Muscle and Nerve, 2013, 48, 161-170.	1.0	21
102	Transient unilateral spatial neglect during aura in a woman with sporadic hemiplegic migraine. Cephalalgia, 2013, 33, 1194-1197.	1.8	2
103	Dopamine Dysregulation Syndrome in Parkinson's Disease Patients on Duodenal Levodopa Infusion. Movement Disorders, 2013, 28, 840-841.	2.2	12
104	Dopamine Dysregulation Syndrome in Parkinsonâ€™s Disease Patients with Unsatisfactory Switching from Immediate to Extended Release Pramipexole: A Further Clue to Incentive Sensitization Mechanisms?. Behavioural Neurology, 2013, 27, 563-566.	1.1	3
105	Structural and Dynamical Insights on HLA-DR2 Complexes That Confer Susceptibility to Multiple Sclerosis in Sardinia: A Molecular Dynamics Simulation Study. PLoS ONE, 2013, 8, e59711.	1.1	43
106	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. PLoS ONE, 2013, 8, e59790.	1.1	25
107	Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis. PLoS ONE, 2013, 8, e67357.	1.1	29
108	Association of Mycobacterium avium subsp. paratuberculosis and SLC11A1 polymorphisms in Sardinian multiple sclerosis patients. Journal of Infection in Developing Countries, 2013, 7, 203-207.	0.5	22

#	Article	IF	Citations
109	Overlapping syndromes in laminopathies: a meta-analysis of the reported literature. Acta Myologica, 2013, 32, 7-17.	1.5	33
110	Dopamine dysregulation syndrome in Parkinson's disease patients with unsatisfactory switching from immediate to extended release pramipexole: a further clue to incentive sensitization mechanisms?. Behavioural Neurology, 2013, 27, 563-6.	1.1	3
111	Are Mycobacterium avium subsp. paratuberculosis and Epsteinâ€“Barr virus triggers of multiple sclerosis in Sardinia?. Multiple Sclerosis Journal, 2012, 18, 1181-1184.	1.4	31
112	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nature Genetics, 2012, 44, 3-5.	9.4	44
113	Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: a peculiar phenotype?. Journal of Neurology, 2012, 259, 1749-1751.	1.8	49
114	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. PLoS ONE, 2012, 7, e41678.	1.1	38
115	Dopaminergic-induced paraphilias associated with impulse control and related disorders in patients with Parkinson disease. Journal of Neurology, 2012, 259, 2752-2754.	1.8	11
116	ALS/FTD phenotype in two Sardinian families carrying bothC9ORF72andTARDBPmutations. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 730-733.	0.9	57
117	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	1.5	76
118	Cardiac and muscle imaging findings in a family with X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2012, 22, 152-158.	0.3	19
119	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	3.7	182
120	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	0.8	82
121	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	0.8	78
122	Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease. Journal of the Neurological Sciences, 2012, 323, 33-39.	0.3	132
123	Population Based Study of 12 Autoimmune Diseases in Sardinia, Italy: Prevalence and Comorbidity. PLoS ONE, 2012, 7, e32487.	1.1	147
124	HLA-DRB1-DQB1 Haplotypes Confer Susceptibility and Resistance to Multiple Sclerosis in Sardinia. PLoS ONE, 2012, 7, e33972.	1.1	34
125	Cardiac involvement in patients with lamin A/C gene mutations: A cohort observation. Muscle and Nerve, 2012, 46, 187-192.	1.0	17
126	Cognitive screening in patients with amyotrophic lateral sclerosis in early stages. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 95-101.	2.3	26

#	Article	IF	Citations
127	Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation. Neurological Sciences, 2012, 33, 863-867.	0.9	10
128	Genome-Wide Association Study of Multiple Sclerosis Confirms a Novel Locus at 5p13.1. PLoS ONE, 2012, 7, e36140.	1.1	46
129	Epidemiology of multiple sclerosis in south-western Sardinia. Multiple Sclerosis Journal, 2011, 17, 1282-1289.	1.4	66
130	Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1009-1013.	2.5	46
131	Association of Mycobacterium avium subsp. paratuberculosis with Multiple Sclerosis in Sardinian Patients. PLoS ONE, 2011, 6, e18482.	1.1	85
132	Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP Gene. Archives of Neurology, 2011, 68, 594.	4.9	104
133	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	0.9	17
134	Aberrant splicing in the LMNA gene caused by a novel mutation on the polypyrimidine tract of intron 5. Muscle and Nerve, 2011, 43, 688-693.	1.0	10
135	Clinical and molecular characterization of limbâ€girdle muscular dystrophy due to LAMA2 mutations. Muscle and Nerve, 2011, 44, 703-709.	1.0	52
136	Dilated cardiomyopathy with conduction defects in a patient with partial merosin deficiency due to mutations in the lamininâ€Î±2â€chain gene: A chance association or a novel phenotype?. Muscle and Nerve, 2011, 44, 826-828.	1.0	32
137	Amyotrophic Lateral Sclerosisâ€"Frontotemporal Lobar Dementia in 3 Families With p.Ala382Thr TARDBP Mutations. Archives of Neurology, 2010, 67, 1002-9.	4.9	53
138	A case of neurofibromatosis and multiple sclerosis. Neurological Sciences, 2010, 31, 631-634.	0.9	10
139	Muscle imaging analogies in a cohort of patients with different clinical phenotypes caused by LMNA gene mutations. Muscle and Nerve, 2010, 41, 458-463.	1.0	44
140	Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nature Genetics, 2010, 42, 495-497.	9.4	164
141	ParkinExon Rearrangements and Sequence Variants inLRRK2Mutations Carriers: Analysis on a Possible Modifier Effect onLRRK2Penetrance. Parkinson's Disease, 2010, 2010, 1-5.	0.6	4
142	Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®). Neuropsychiatric Disease and Treatment, 2010, 6, 483.	1.0	16
143	Heat shock protein 27 R127W mutation: evidence of a continuum between axonal Charcot-Marie-Tooth and distal hereditary motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 958-962.	0.9	33
144	Analyzing Histopathological Features of Rare Charcot-Marie-Tooth Neuropathies to Unravel Their Pathogenesis. Archives of Neurology, 2010, 67, 1498-505.	4.9	48

#	Article	IF	Citations
145	Dopaminergic drugs, paraphilic fantasies, paraphilic behaviours and creativity in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 563-564.	2.5	1
146	A Novel Mutation in Lamin A/C Gene: Phenotype and Consequences on the Protein Structure and Flexibility. SRX Biology, 2010, 2010, 1-7.	0.0	2
147	Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population. Multiple Sclerosis Journal, 2009, 15, 1030-1036.	1.4	3
148	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	0.9	68
149	The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. Neurological Sciences, 2009, 30, 163-165.	0.9	16
150	Reversible Pisa syndrome in patients with Parkinsonâ€™s disease on dopaminergic therapy. Journal of Neurology, 2009, 256, 390-395.	1.8	81
151	Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes and Immunity, 2009, 10, 15-17.	2.2	69
152	Carpal tunnel syndrome triggered by excessive licorice consumption. Journal of the Peripheral Nervous System, 2009, 14, 64-65.	1.4	6
153	Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: Importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism and Related Disorders, 2009, 15, 277-280.	1.1	28
154	Othello Syndrome in Parkinson Disease Patients Without Dementia. Neurologist, 2009, 15, 34-36.	0.4	38
155	Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Functional Neurology, 2009, 24, 159-62.	1.3	42
156	Lateral trunk flexion and Pisa syndrome in Parkinson's disease. Are they really always different conditions although denoting similar features?. Journal of Neurology, 2008, 255, 450-451.	1.8	3
157	Genetic loci linked to Type 1 Diabetes and Multiple Sclerosis families in Sardinia. BMC Medical Genetics, 2008, 9, 3.	2.1	21
158	Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinsonâ€™s disease patient. Journal of the Neurological Sciences, 2008, 275, 154-156.	0.3	30
159	Muscle MRI findings in patients with an apparently exclusive cardiac phenotype due to a novel LMNA gene mutation. Neuromuscular Disorders, 2008, 18, 291-298.	0.3	24
160	Ultrarapid mood cycling in a Parkinsonian patient: Is not always simply an â€œonâ€“offâ€•fluctuationâ€”A case report. Parkinsonism and Related Disorders, 2008, 14, 262-263.	1.1	1
161	Pathological gambling, delusional parasitosis and adipsia as a post-haemorrhagic syndrome: A case report. Neurocase, 2008, 14, 385-389.	0.2	6
162	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	1.4	72

#	Article	IF	Citations
163	Efficacy and Safety of Quetiapine Treatment for Delusional Parasitosis. Clinical Neuropharmacology, 2008, 31, 310-312.	0.2	10
164	Oxcarbazepine-Induced Leukopenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2008, 20, 502-503.	0.9	7
165	mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis. PLoS ONE, 2008, 3, e1530.	1.1	64
166	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 975-980.	1.4	23
167	Communicating the diagnosis of multiple sclerosis - a qualitative study. Multiple Sclerosis Journal, 2007, 13, 763-769.	1.4	77
168	Parental transmission of multiple sclerosis: Maternal, paternal, or neither?. Neurology, 2007, 69, 1202-1203.	1.5	1
169	Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 1200-1202.	1.4	39
170	A novel mutation in the central rod domain of lamin A/C producing a phenotype resembling the Emeryâ€“Dreifuss muscular dystrophy phenotype. Muscle and Nerve, 2007, 36, 828-832.	1.0	8
171	Variation of the Myelin Oligodendrocyte Glycoprotein gene is not primarily associated with multiple sclerosis in the Sardinian population. BMC Genetics, 2007, 8, 25.	2.7	6
172	The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2007, 183, 208-213.	1.1	12
173	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€“116]. Journal of Neuroimmunology, 2007, 189, 175-176.	1.1	1
174	Susceptibility to multiple sclerosis: the role of interleukin genes. Lancet Neurology, The, 2007, 6, 846-847.	4.9	1
175	Aberrant sexual behaviours in Parkinsonâ€™s disease during dopaminergic treatment. Journal of Neurology, 2007, 254, 110-112.	1.8	31
176	Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132.	0.9	57
177	Hypersexual behaviour, frotteurism and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: A rare case of iatrogenic paraphilia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1539-1541.	2.5	43
178	Medulloblastoma Induces unusual Headache with Clinical Picture of Basilar-Type Migraine Complicated by Ischaemic Infarcts. Cephalalgia, 2006, 26, 1238-1241.	1.8	5
179	Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. Journal of Neurology, 2006, 253, 208-213.	1.8	12
180	A novel Cx32 mutation causes X-linked Charcot-Marie-Tooth disease with brainstem involvement and brain magnetic resonance spectroscopy abnormalities. Neurological Sciences, 2006, 27, 18-23.	0.9	35

#	Article	IF	Citations
181	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	1.1	29
182	Prevalence of primary blepharospasm in Sardinia, Italy: A service-based survey. Movement Disorders, 2006, 21, 2005-2008.	2.2	30
183	Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Annals of Neurology, 2006, 59, 634-639.	2.8	69
184	Treatment of refractory chronic inflammatory demyelinating polyneuropathy with interferon Î²1B. Journal of Neurology, 2005, 252, 1420-1422.	1.8	7
185	The co-inheritance of type 1 diabetes and multiple sclerosis in Sardinia cannot be explained by genotype variation in the HLA region alone. Human Molecular Genetics, 2004, 13, 2919-2924.	1.4	41
186	Heterogeneity in the Magnitude of the Insulin Gene Effect on HLA Risk in Type 1 Diabetes. Diabetes, 2004, 53, 3286-3291.	0.3	30
187	PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients. Journal of Neurology, 2004, 251, 1085-8.	1.8	11
188	Allogeneic hematopoietic stem cell transplantation in a patient affected by large granular lymphocyte leukemia and multiple sclerosis. Annals of Hematology, 2004, 83, 403-405.	0.8	29
189	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 31-38.	1.1	12
190	A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 120-123.	1.1	16
191	Prospective study of multiple sclerosis with early onset. Multiple Sclerosis Journal, 2002, 8, 115-118.	1.4	134
192	Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet, The, 2002, 359, 1461-1465.	6.3	112
193	Chromosome 7q21â€“22 and multiple sclerosis: evidence for a genetic susceptibility effect in vicinity to the protachykinin-1 gene. Journal of Neuroimmunology, 2002, 125, 141-148.	1.1	23
194	Age-related disability in multiple sclerosis. Annals of Neurology, 2002, 51, 475-480.	2.8	163
195	Lack of evidence for a role of the myelin basic protein gene in multiple sclerosis susceptibility in Sardinian patients. Journal of Neurology, 2002, 249, 1552-1555.	1.8	6
196	Linkage disequilibrium analysis of chromosome 12q14â€“15 in multiple sclerosis: delineation of a 118-kb interval around interferon-Î³ (IFNG) that is involved in male versus female differential susceptibility. Genes and Immunity, 2002, 3, 470-476.	2.2	40
197	A genome screen for multiple sclerosis in Sardinian multiplex families. European Journal of Human Genetics, 2001, 9, 621-626.	1.4	95
198	Novel polymorphisms in the IL-10 related AK155 gene (chromosome 12q15). Genes and Immunity, 2001, 2, 284-286.	2.2	29

#	Article	IF	Citations
199	The contribution of HLA to multiple sclerosis susceptibility in Sardinian affected sibling pairs. Annals of Neurology, 2000, 47, 411-412.	2.8	7
200	Cytokines and multiple sclerosis severity: No correlation among Sardinians. Annals of Neurology, 2000, 48, 816-816.	2.8	4
201	Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. Journal of Neuroimmunology, 2000, 105, 58-63.	1.1	46
202	PECAM1, MPO and PRKAR1A at chromosome 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia. Journal of Neuroimmunology, 2000, 108, 153-159.	1.1	28
203	ICAM-1 gene is not associated with multiple sclerosis in sardinian patients. Journal of Neurology, 2000, 247, 677-680.	1.8	14
204	The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex diseases. Human Molecular Genetics, 2000, 9, 2959-2965.	1.4	62
205	Analysis of an IFN- gamma gene (IFNG) Polymorphism in Multiple Sclerosis in Europe: Effect of Population Structure on Association with Disease. Journal of Interferon and Cytokine Research, 1999, 19, 1037-1046.	0.5	41
206	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics, 1999, 7, 377-385.	1.4	38
207	Cytokine production in patients carrying multiple sclerosis-linked HLA-DR alleles. Journal of Neurology, 1999, 246, 1194-1196.	1.8	8
208	Tumor necrosis factor 2 allele does not contribute to increased tumor necrosis factor-? production in Sardinian multiple sclerosis. Annals of Neurology, 1999, 46, 799-800.	2.8	12
209	Interferon-? gene polymorphism-associated risk for multiple sclerosis in sardinia. Annals of Neurology, 1998, 44, 841-842.	2.8	34
210	Multiple Sclerosis in Sardinia Is Associated and in Linkage Disequilibrium with HLA-DR3 and -DR4 Alleles. American Journal of Human Genetics, 1997, 61, 454-457.	2.6	111
211	Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. Journal of Neuroimmunology, 1997, 76, 189-192.	1.1	91
212	Multiple Sclerosis in Sardinia Is Associated and in Linkage Disequilibrium with HLAâ€ÐR3 and â€ÐR4 Alleles. American Journal of Human Genetics, 1997, 61, 454-457.	2.6	86
213	Continuous Infusion of Apomorphine Improves Torsion Dystonia in a Boy Unresponsive to Other Dopaminergic Drugs. Journal of Child Neurology, 1996, 11, 343-345.	0.7	3
214	Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis. Italian Journal of Neurological Sciences, 1994, 15, 153-155.	0.1	6
215	Familial cardiomyopathy, mental retardation and myopathy associated with desmin-type intermediate filaments. Neuromuscular Disorders, 1994, 4, 233-241.	0.3	55
216	Deletion of the Dystrophin Muscle-Promoter Region Associated with X-Linked Dilated Cardiomyopathy. New England Journal of Medicine, 1993, 329, 921-925.	13.9	412

#	Article	IF	Citations
217	Role of Predisposing and Protective HLA-DQA and HLA-DQB Alleles in Sardinian Multiple Sclerosis. Archives of Neurology, 1993, 50, 256-260.	4.9	22
218	Polymerase Chain Reaction Analysis for Specific HTLV-1 Sequences from Cerebrospinal Fluid and Peripheral Blood Cells in Sardinian Multiple Sclerosis Patients. European Neurology, 1992, 32, 195-198.	0.6	1
219	Variable dystrophin expression in different muscles of a Duchenne muscular dystrophy carrier. Clinical Genetics, 1992, 42, 35-38.	1.0	19
220	Imbalance of CSF Lymphocyte Subsets in Multiple Sclerosis. , 1990, , 59-65.		1
221	Cerebrospinal fluid lymphocyte subpopulations in multiple sclerosis. Italian Journal of Neurological Sciences, 1986, 7, 101-105.	0.1	3
222	Subacute sclerosing panencephalitis in Italy. Acta Neurologica Scandinavica, 1986, 73, 160-167.	1.0	4
223	Subacute Sclerosing Panencephalitis and Hypoparathyroidism. European Neurology, 1985, 24, 149-152.	0.6	2
224	Lymphocyte subpopulations in blood and cerebrospinal fluid from patients with subacute sclerosing panencephalitis. Acta Neurologica Scandinavica, 1983, 67, 55-63.	1.0	11
225	Surface markers on lymphocytes from human cerebrospinal fluid. Journal of Neuroimmunology, 1983, 5, 325-331.	1.1	19
226	Subacute Sclerosing Panencephalitis in Only One of Identical Twins. European Neurology, 1983, 22, 428-432.	0.6	14
227	Surface Markers on Lymphocytes from Human Cerebrospinal Fluid. European Neurology, 1980, 19, 241-246.	0.6	9